Free Trial Information
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...of shares and price range upsized from 8.3 million at $17-$19. Cullinan launched in 2017 as Cullinan Oncology LLC...
Read More
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...NASDAQ:ZLAB; HKEX:9688) gained an exclusive license from Cullinan Oncology LLC...
...Generic), Jakavi (Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos Inc. Cullinan Oncology LLC Zai...
Read More
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...NASDAQ:XFOR) appointed Art Taveras as CSO. He was CSO of Comet Therapeutics Inc. Jeffrey Trigilio joined Cullinan Oncology LLC...
Read More
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM Therapeutics Cullinan Oncology LLC Bayer...
Read More
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...of Molecular Biotechnology and the Research Institute of Molecular Pathology. Cullinan, MIT form cytokine company Cullinan Oncology LLC...
...DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics (Shanghai) Co. Ltd. Eureka Therapeutics Nanjing TransThera Biosciences Co. Ltd. Cullinan Oncology LLC Quantro...
Read More
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology LLC...
...A NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1 Lauren Martz, Senior Editor Cullinan Oncology LLC PDI...
Read More
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...While most small biotechs are focused on either a platform technology or an individual asset, Cullinan Oncology LLC...
...growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho Ventures LLC Cullinan Oncology LLC Epstein-Barr...
Read More
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...20 insertion mutation. “All the negotiations, terms sheets and discussions were done by Taiho Ventures.” Cullinan Oncology LLC...
Read More
BioCentury | Feb 8, 2019
Company News

Taiho, Cullen partner to develop TAS6417

...company said details are not disclosed. Taiho's strategic corporate venture arm, Taiho Ventures LLC, and Cullinan Oncology...
...Cullen Pearl is a newly formed subsidiary of Cullinan Oncology LLC (Cambridge, Mass.). Cullinan Pearl will utilize Cullinan Oncology’s...
...TAS6417, an epidermal growth factor receptor tyrosine kinase inhibitor. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Cullinan Oncology LLC...
Read More
BioCentury | Aug 10, 2018
Finance

Super-sized ambitions

...companies to that event so that they won't be dependent on capital markets." MPM launched Cullinan Oncology LLC...
...Texas BioNTech AG, Mainz, Germany Celgene Corp. (NASDAQ:CELG), Summit, N.J. Compass Therapeutics LLC, Cambridge, Mass. Cullinan Oncology LLC...
Read More
Items per page:
1 - 10 of 13
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...of shares and price range upsized from 8.3 million at $17-$19. Cullinan launched in 2017 as Cullinan Oncology LLC...
Read More
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...NASDAQ:ZLAB; HKEX:9688) gained an exclusive license from Cullinan Oncology LLC...
...Generic), Jakavi (Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos Inc. Cullinan Oncology LLC Zai...
Read More
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...NASDAQ:XFOR) appointed Art Taveras as CSO. He was CSO of Comet Therapeutics Inc. Jeffrey Trigilio joined Cullinan Oncology LLC...
Read More
BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

...FMS-like tyrosine kinase 3 BC Staff NIH 89bio Takeda Nestle S.A. AIMM Therapeutics Cullinan Oncology LLC Bayer...
Read More
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...of Molecular Biotechnology and the Research Institute of Molecular Pathology. Cullinan, MIT form cytokine company Cullinan Oncology LLC...
...DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics (Shanghai) Co. Ltd. Eureka Therapeutics Nanjing TransThera Biosciences Co. Ltd. Cullinan Oncology LLC Quantro...
Read More
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology LLC...
...A NKG2D (KLRK1; CD314) - Killer cell lectin-like receptor subfamily K member 1 Lauren Martz, Senior Editor Cullinan Oncology LLC PDI...
Read More
BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...While most small biotechs are focused on either a platform technology or an individual asset, Cullinan Oncology LLC...
...growth factor receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho Ventures LLC Cullinan Oncology LLC Epstein-Barr...
Read More
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...20 insertion mutation. “All the negotiations, terms sheets and discussions were done by Taiho Ventures.” Cullinan Oncology LLC...
Read More
BioCentury | Feb 8, 2019
Company News

Taiho, Cullen partner to develop TAS6417

...company said details are not disclosed. Taiho's strategic corporate venture arm, Taiho Ventures LLC, and Cullinan Oncology...
...Cullen Pearl is a newly formed subsidiary of Cullinan Oncology LLC (Cambridge, Mass.). Cullinan Pearl will utilize Cullinan Oncology’s...
...TAS6417, an epidermal growth factor receptor tyrosine kinase inhibitor. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Cullinan Oncology LLC...
Read More
BioCentury | Aug 10, 2018
Finance

Super-sized ambitions

...companies to that event so that they won't be dependent on capital markets." MPM launched Cullinan Oncology LLC...
...Texas BioNTech AG, Mainz, Germany Celgene Corp. (NASDAQ:CELG), Summit, N.J. Compass Therapeutics LLC, Cambridge, Mass. Cullinan Oncology LLC...
Read More
Items per page:
1 - 10 of 13